Association of serum fibroblast growth factor 21 and urinary glucose excretion in hospitalized patients with type 2 diabetes

Rui Zhang,Xiaoling Cai,Yongrui Du,Liu Liu,Xueyao Han,Wei Liu,Siqian Gong,Xianghai Zhou,Xiangqing Wang,Xin Wen,Linong Ji
DOI: https://doi.org/10.1016/j.jdiacomp.2020.107750
IF: 3.219
2021-01-01
Journal of Diabetes and its Complications
Abstract:<p>Aim</p><p>Urinary glucose excretion (UGE) is mainly regulated by the sodium glucose cotransporter (SGLT) -2 in the proximal tubule of kidney. Lowered UGE was associated with higher extent of insulin resistance in patients with type 2 diabetes. Animal studies suggested the relation of Fibroblast growth factor 21 (FGF21) and UGE. However, little was known about the association of FGF21 and UGE in human. We conducted a study to investigate the association of serum FGF21 and low UGE in patients with type 2 diabetes.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Method</h3><p>A cohort of 2066 hospitalized patients with type 2 diabetes was screened for the fasting urinary glucose concentration and fasting blood glucose in the medical records. 70 patients with high UGE and 61 patients with Low UGE were analyzed. Frozen serum samples were used for the test of FGF21 levels.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>The body mass index (BMI) and serum FGF21 levels were higher in low UGE group. Multivariable logistic regression indicated the association of FGF21 and low UGE after adjusting for age, sex, renal function, fasting plasm glucose, the treatment of insulin, and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) index.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>Higher serum FGF21 levels were independently associated with low UGE in patients with type 2 diabetes.</p>
endocrinology & metabolism
What problem does this paper attempt to address?
This paper aims to explore the relationship between serum fibroblast growth factor 21 (FGF21) and urinary glucose excretion (UGE), particularly in hospitalized patients with type 2 diabetes. The research background includes the following key points: 1. **Role of the kidneys in glucose homeostasis**: The kidneys reabsorb about 90% of filtered glucose through sodium-glucose co-transporters (SGLT-2) in the proximal tubules. The renal glucose threshold refers to the concentration beyond which the capacity of SGLT-2 is saturated, leading to the onset of urinary glucose excretion. 2. **Role of SGLT-2 inhibitors**: Increasing urinary glucose excretion not only helps lower blood glucose levels but also improves complications such as obesity, hypertension, cardiovascular diseases, and chronic kidney disease. 3. **Individual differences in urinary glucose excretion**: There are differences in UGE among individuals. Low UGE is associated with higher insulin resistance, and some genetic mutations may also lead to high UGE. Previous studies have shown that FGF21 plays an important role in metabolic regulation and that its levels are elevated in patients with metabolic disorders. However, the relationship between FGF21 and UGE remains unclear. Therefore, the main objective of this study is to investigate the association between serum FGF21 levels and low UGE in hospitalized patients with type 2 diabetes. The research methods included screening 2066 hospitalized patients with type 2 diabetes, and ultimately analyzing the serum FGF21 levels of 70 patients in the high UGE group and 61 patients in the low UGE group. The results showed that patients in the low UGE group had higher BMI and serum FGF21 levels. Multivariable logistic regression analysis indicated that after adjusting for factors such as age, gender, renal function, fasting blood glucose, insulin therapy, and insulin resistance index (HOMA-IR), FGF21 levels remained independently associated with low UGE.